Effect of Memantine on Functional Communication in Patients With Alzheimer's Disease

• Status: Completed
• Trial end date: 2008-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study is to evaluate the effect of memantine versus placebo on functional communication in patients with Alzheimer's Disease

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Forest Laboratories
• Treatments: Memantine

Criteria

Inclusion Criteria:

• Male and female outpatients, 50 years or older, native English speakers, meeting National Institute of Neurological and Communicative Disorders and Stroke--Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria for probable AD with a Mini Mental State Examination (MMSE) score of 10 to 19 at Screening and Baseline

Exclusion Criteria:

• Current Diagnostic and Statistical Manual of Mental Disorders--Fourth Edition (DSM-IV) Axis I disorder other than AD

• Previous imaging results not consistent with the diagnosis of AD

• Modified Hachinski Ischemia Score greater than 4

• Evidence of other neurologic disorders

• Clinically significant systemic disease

• A known or suspected history of alcohol or drug abuse in the past 5 years

• Taking excluded medication

• Previous treatment with commercial memantine